TREVENA, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2015-12-23: Form 8-K; Period of report 2015-12-23; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
- 2015-12-14: Form 8-K; Period of report 2015-12-14; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2015-12-11: Form 8-K; Period of report 2015-12-10; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2015-11-10: Form 8-K; Period of report 2015-11-10; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2015-12-23 | 8-K | 2015-12-23 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 is incorporated by reference into this Item 2.03. 3.02 The information set forth in Item 1.01 regarding the Warrants is incorporated by reference into this Item 3.02. | a15-24888_38k.htm |
| 2015-12-14 | 8-K | 2015-12-14 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a15-24888_28k.htm |
| 2015-12-11 | 8-K | 2015-12-10 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a15-24888_18k.htm |
| 2015-11-10 | 8-K | 2015-11-10 | 2.02 Results of Operations and Financial Condition | 2.02 The information under this caption and contained in the press release attached hereto as Exhibit 99.1 is furnished by Trevena, Inc. (the “Company”) in accordance with Securities Exchange Commission Release No. 33-8216. | a15-22722_18k.htm |
| 2015-10-28 | 8-K | 2015-10-28 | 7.01 Regulation FD Disclosure | 7.01 On October 28, 2015, Trevena, Inc. (“Trevena” or the “Company”) will be hosting analysts and investors in New York City from 12:00 p.m. | a15-21844_18k.htm |
| 2015-09-21 | 8-K | 2015-09-16 | 8.01 Other Events | 8.01 On September 16, 2015, Trevena, Inc. (the “Company”) issued a press release announcing the closing of its previously announced underwritten offering of 7,475,000 shares of its common stock, including the sale of 975,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $9.75 per share (the “Offering”). | a15-19974_18k.htm |
| 2015-09-14 | 8-K | 2015-09-10 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On September 10, 2015, the Company issued a press release announcing the Offering. | a15-19311_18k.htm |
| 2015-08-31 | 8-K | 2015-08-31 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 In connection with its press release dated August 31, 2015, Trevena, Inc. (the “Company”) will hold a conference call and webcast on August 31, 2015. 8.01 On August 31, 2015, the Company announced results from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate to severe postoperative pain after abdominoplasty surgery. | a15-18776_18k.htm |
| 2015-08-11 | 8-K | 2015-08-11 | 2.02 Results of Operations and Financial Condition | 2.02 The information under this caption and contained in the press release attached hereto as Exhibit 99.1 is furnished by Trevena, Inc. (the “Company”) in accordance with Securities Exchange Commission Release No. 33-8216. | a15-12133_38k.htm |
| 2015-07-21 | 8-K | 2015-07-20 | 8.01 Other Events | 8.01 Effective as of July 20, 2015, Yacoub Habib, Ph.D., joined Trevena, Inc. as Senior Vice President, Business Development and Corporate Planning. | a15-15114_28k.htm |
| 2015-07-02 | 8-K | 2015-06-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On June 29, 2015, Francois Nader, M.D., provided Trevena, Inc. (the “Company”) with notice of his intention to resign from the Board of Directors of the Company (the “Board”), effective as June 30, 2015. | a15-15114_18k.htm |
| 2015-05-21 | 8-K | 2015-05-20 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On May 20, 2015, the Company held its Annual Meeting in King of Prussia, Pennsylvania. | a15-11495_28k.htm |
| 2015-05-13 | 8-K | 2015-05-13 | 8.01 Other Events | 8.01 On May 13, 2015, Trevena, Inc. (the “Company”) completed the sale of 2,700,000 shares of its common stock, par value $0.001 per share, at a weighted average price per share of $6.2503, for aggregate net proceeds of approximately $16.3 million. | a15-11495_18k.htm |
| 2015-05-07 | 8-K | 2015-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 The information under this caption and contained in the press release attached hereto as Exhibit 99.1 is furnished by Trevena, Inc. (the “Company”) in accordance with Securities Exchange Commission Release No. 33-8216. | a15-10935_18k.htm |
| 2015-05-05 | 8-K | 2015-05-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 (e) On May 4, 2015, Trevena, Inc. (“Trevena” or the “Company”) amended its existing employment agreements with each of its executive officers (the “Amendments”). 8.01 Effective as of May 4, 2015, Carrie L. Bourdow joined Trevena as Senior Vice President and Chief Commercial Officer. | a15-10562_18k.htm |
| 2015-04-13 | 8-K | 2015-04-13 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a15-9021_18k.htm |
| 2015-04-03 | 8-K | 2015-04-03 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a15-8478_18k.htm |
| 2015-03-23 | 8-K | 2015-03-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 17, 2015, the Board of Directors (the “Board”) of Trevena, Inc. (the “Company”) (i) approved a cash bonus award for fiscal year 2014 to be made to Maxine Gowen, Ph.D., the President and Chief Executive Officer (the “CEO”) of the Company, and (ii) ratified cash bonus awards for fiscal year 2014 that were approved by the Compensation Committee of the Board for the Company’s executive officers other than the CEO. | a14-26722_58k.htm |
| 2015-03-18 | 8-K | 2015-03-18 | 2.02 Results of Operations and Financial Condition | 2.02 The information under this caption and contained in the press release attached hereto as Exhibit 99.1 is furnished by Trevena, Inc. (the “Company”) in accordance with Securities Exchange Commission Release No. 33-8216. | a14-26722_48k.htm |
| 2015-03-10 | 8-K | 2015-03-05 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 Based on a review of the safety and efficacy data from 254 study patients enrolled in the Study to date, the Company announced on March 9, 2015 that it has agreed with Actavis to weight future enrollment in the Study toward the most promising dose and to increase target enrollment in the Study from 500 patients to 620 patients. | a15-6451_18k.htm |
| 2015-01-05 | 8-K | 2015-01-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (e) Effective as of January 1, 2015, the Board of Directors (the “Board”) of Trevena, Inc. (the “Company”) approved the adoption of the Trevena, Inc. Incentive Compensation Plan (the “ICP”). | a15-1051_18k.htm |